CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 4, 2002, Pages 280-285

  Anderson, Peter L ^a   Brundage, Richard C ^a   Kakuda, Thomas N ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 0036229917     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121910     Document Type: Article

References (19)

1. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
2. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
3. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
4. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy
5. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
6. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir
7. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection
8. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
9. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
10. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors
11. How an inhibitor of the HIV-I protease modulates proteasome activity
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
13. Role of intestinal P-glycoprotein (MDR1) in interpatient variation in the oral bioavailability of cyclosporine
14. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
15. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
16. St John's wort modulates both expression and function of P glycoprotein in peripheral blood lymphocytes
17. Indinavir concentrations and St John's wort
18. Characterization of St. Johns wort use in a community clinic: Lack of association with viral breakthrough
19. Clinical pharmacologic considerations for HIV-1 protease inhibitors